Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 7Gastrointestinal Neoplasms 3Colonic Neoplasms 3Rectal Neoplasms 2Cholangiocarcinoma 2Untreated Resectable Pancreatic Adenocarcinoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Resectable 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Klatskin Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

pembrolizumab 25Nivolumab 20atezolizumab 8Magnetic Resonance Spectroscopy 7Ipilimumab 7Specimen Handling 5Paclitaxel 5Fluorodeoxyglucose F18 4Cyclophosphamide 4Carboplatin 4fludarabine 3durvalumab 3avelumab 3Interleukin-2 3Gemcitabine 3Docetaxel 3130-nm albumin-bound paclitaxel 3tislelizumab 2spartalizumab 2regorafenib 2epacadostat 2cabozantinib 2aldesleukin 2Taxes 2Pemetrexed 2FAPI-46 2Cisplatin 2Albumin-Bound Paclitaxel 2zanidatamab 1veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Hydroxychloroquine × Gastrointestinal × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡